Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling